Apollina Goel

Apollina Goel is an experienced professional in translational medicine and biomarkers, currently serving as Director of Translational Biomarkers in the Late ADC Oncology Group at Daiichi Sankyo US since November 2024, focusing on the HER3-DXd portfolio. Previously, as Director of Translational Medicine at Cue Biopharma from October 2021 to October 2024, Apollina led the development of biomarker-driven strategies for clinical trials and collaborated on regulatory submissions. Apollina's career includes significant roles at Invicro and as a tenured Associate Professor at the University of Iowa, where research centered on cancer, inflammation, and redox metabolism. Apollina holds a PhD in biotechnology from the CSIR Institute of Microbial Technology and has contributed extensively to both academic and industry settings.